Lipoprotéine(a) et microcalcification de la valve aortique
|Abstract:||Aortic stenosis (AS) is the most common valve disease in our society. It is characterized by fibrocalcific remodelling leading to progressive obstruction of blood flow. Lipoprotein(a) (Lp[a]), a lipoprotein similar to low-density lipoprotein, is a genetic risk factor strongly associated with AS. Plasma concentrations of Lp(a) are very little influenced by extrinsic factors, such as diet or lipid-lowering medication. Studies suggest that Lp(a) would be associated with calcification processes in the development of AS. Positron emission tomography coupled with computed tomography allows the early process related to calcification of the aortic valve to be detected. This nuclear imaging technique identifies and quantifies microcalcification at the aortic valve, a marker strongly linked to the future development of calcium. The impact of Lp(a) on aortic valve microcalcification has never been evaluated. Microcalcification measurements in individuals without AS with high or low concentrations of Lp(a) were performed. Our hypothesis was that individuals with high concentrations of Lp(a) have higher microcalcification when compared to individuals with lower concentrations of Lp(a). The results of this study revealed that individuals without AS but with high concentrations of Lp(a) have a higher microcalcification than individuals with lower concentrations of Lp(a). The completion of this research project allowed us to observe clinically an active calcification process in individuals with high concentrations of Lp(a) despite the clinical absence of the disease, illustrating the importance of this lipoprotein in the development of AS.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||13 March 2020|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.